Pediatric Open-Label Extension Study

Inclusion Criteria:

• Written informed consent from parent(s) or legal guardian(s) with sufficientintellectual capacity to understand the study and support subjects' participation inthe study procedures must be obtained for subjects who are not emancipated. Inaccordance with Institutional Review Board (IRB) or Independent Ethics Committee (IEC)requirements, the subject will complete an informed assent when developmentallyappropriate, to participate in the study before conduct of any study-specificprocedures.

• Subject has completed Study D1050301 (Visit 9) OR

• Subject has completed Study D1050325 (Visit 9) OR

• Subject has completed Study D1050326 (Visit 8)

• Subject is judged by the investigator to be appropriate for participation in a 104-week clinical trial in an outpatient setting involving open-label lurasidonetreatment, and is able to comply with the protocol.

• A reliable informant (eg, parent, legal guardian, or caregiver) must be available toaccompany the subject at each visit. For subjects entering from Study D1050325, thereliable caregiver must also oversee the administration of the study drug throughoutthe study

• Females who participate in this study:

• are unable to become pregnant (eg, premenarchal, surgically sterile, etc.) -OR-

• practices true abstinence (consistent with lifestyle) and must agree to remainabstinent from signing informed consent to at least 7 days after the last dose ofstudy drug has been taken; -OR-

• are sexually active and willing to use a medically effective method of birthcontrol (eg, male using condom and female using condom, diaphragm, contraceptivesponge, spermicide, contraceptive pill, or intrauterine device) from signinginformed consent to at least 7 days after the last dose of study drug has beentaken.

• Males must be willing to remain sexually abstinent (consistent with lifestyle) or usean effective method of birth control (eg, male using condom and female using condom,diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterinedevice) from signing informed consent to at least 7 days after the last dose of studydrug has been taken.

Exclusion Criteria:

• Subject is considered by the investigator to be at imminent risk of suicide.

• Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardivedyskinesia, or any other moderate or severe movement disorder. Severity to bedetermined by the investigator.